Innovent’s Mazdutide 9 mg Moves One Step Closer to Approval in China

China may soon have a powerful new option for treating moderate to severe obesity.
Innovent Biologics announced that the National Medical Products Administration (NMPA) has accepted the supplementary application for mazdutide 9 mg, a next-generation dual GCG/GLP-1 receptor agonist designed for long-term weight management.

The drug targets a major unmet need in China, where treatment options for severe obesity remain limited and often invasive.

Backed by Strong Phase 3 Results

The application is based on data from GLORY-2, a phase 3 trial in Chinese adults with moderate to severe obesity.
The trial hit all primary and key secondary endpoints.

Headline Results from Week 60

• 18.55% mean weight loss with mazdutide 9 mg vs 3.02% with placebo.
• 44% of patients achieved ≥20% weight reduction, compared to 2.6% on placebo.
• In participants without type 2 diabetes, weight loss reached 20.08%, with 48.7% achieving ≥20% reduction.

Notably, weight loss continued without plateau, a rare outcome for obesity drugs after one year.

Impact Beyond the Scale

Mazdutide delivered meaningful metabolic improvements:

• 71.9% reduction in liver fat content
• Significant reductions in blood pressure, lipids, uric acid
• Notable decreases in waist circumference

Safety remained favorable, with no new signals reported.

Detailed data will be shared at upcoming global conferences.

Why This Matters for China?

Professor Linong Ji, a leading endocrinologist and principal investigator, highlighted a key challenge:

Patients with severe obesity (BMI > 32.5 kg/m²) often have only one option—metabolic surgery.

But surgery is invasive, costly, and often underused due to patient hesitation.

Mazdutide 9 mg could become a high-precision oral alternative with weight-loss efficacy approaching surgical levels. This makes the drug a potential breakthrough for millions of patients who lack practical long-term solutions.

Innovent’s Growing Obesity Portfolio

Dr. Lei Qian, Chief R&D Officer, emphasized Innovent’s strategy: a stratified, personalized dosing system.

• 2 mg–4 mg–6 mg for broad overweight and obese populations
• 3 mg–6 mg–9 mg specifically for severe obesity

Mazdutide 9 mg is currently the only GLP-1-based therapy in China to show over 20% weight loss in non-diabetic adults after one year with a simple, two-step titration.

Powered by Dual-Pathway Science

Mazdutide is a mammalian oxyntomodulin analogue licensed exclusively from Eli Lilly for China.
It activates both:

• GLP-1 receptors — supporting glucose control and appetite reduction
• Glucagon receptors — increasing energy expenditure and improving liver fat metabolism

This dual action drives broad metabolic benefits beyond weight loss.

Innovent’s progress signals a major shift in China’s obesity treatment landscape. If approved, mazdutide 9 mg could redefine long-term weight management for patients who have had limited, often invasive choices.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!